These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 8395752)
1. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. Arnold R; Neuhaus C; Benning R; Schwerk WB; Trautmann ME; Joseph K; Bruns C World J Surg; 1993; 17(4):511-9. PubMed ID: 8395752 [TBL] [Abstract][Full Text] [Related]
2. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099 [TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222 [TBL] [Abstract][Full Text] [Related]
5. Gastroenteropancreatic endocrine tumors: effect of Sandostatin on tumor growth. The German Sandostatin Study Group. Arnold R; Benning R; Neuhaus C; Rolwage M; Trautmann ME Metabolism; 1992 Sep; 41(9 Suppl 2):116-8. PubMed ID: 1518429 [TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Arnold R; Benning R; Neuhaus C; Rolwage M; Trautmann ME Digestion; 1993; 54 Suppl 1():72-5. PubMed ID: 8359572 [TBL] [Abstract][Full Text] [Related]
7. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. Kwekkeboom DJ; Teunissen JJ; Bakker WH; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; Esser JP; Kam BL; Krenning EP J Clin Oncol; 2005 Apr; 23(12):2754-62. PubMed ID: 15837990 [TBL] [Abstract][Full Text] [Related]
8. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours. Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100 [TBL] [Abstract][Full Text] [Related]
9. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Reubi JC; Kvols LK; Waser B; Nagorney DM; Heitz PU; Charboneau JW; Reading CC; Moertel C Cancer Res; 1990 Sep; 50(18):5969-77. PubMed ID: 2168286 [TBL] [Abstract][Full Text] [Related]
11. Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Wynick D; Anderson JV; Williams SJ; Bloom SR Clin Endocrinol (Oxf); 1989 Apr; 30(4):385-8. PubMed ID: 2557179 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of gastrointestinal neuroendocrine tumors with the somatostatin analog octreotide (Sandostatin)]. Stöckmann F; Creutzfeldt W Z Gastroenterol; 1988 Oct; 26(10):665-75. PubMed ID: 2849248 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Kvols LK; Brown ML; O'Connor MK; Hung JC; Hayostek RJ; Reubi JC; Lamberts SW Radiology; 1993 Apr; 187(1):129-33. PubMed ID: 8383865 [TBL] [Abstract][Full Text] [Related]
14. An important new treatment for carcinoid tumors and VIPomas. Oncology (Williston Park); 1988 Dec; 2(12):35-6. PubMed ID: 2856315 [No Abstract] [Full Text] [Related]
15. Somatostatin-receptor imaging in the localization of endocrine tumors. Lamberts SW; Bakker WH; Reubi JC; Krenning EP N Engl J Med; 1990 Nov; 323(18):1246-9. PubMed ID: 2170840 [TBL] [Abstract][Full Text] [Related]
16. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues. Arnold R; Frank M; Kajdan U Digestion; 1994; 55 Suppl 3():107-13. PubMed ID: 7698532 [TBL] [Abstract][Full Text] [Related]
17. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Trendle MC; Moertel CG; Kvols LK Cancer; 1997 Feb; 79(4):830-4. PubMed ID: 9024721 [TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogs in the management of gastrointestinal tumors. Lamberts SW Horm Res; 1988; 29(2-3):118-20. PubMed ID: 2900191 [TBL] [Abstract][Full Text] [Related]
19. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Saltz L; Trochanowski B; Buckley M; Heffernan B; Niedzwiecki D; Tao Y; Kelsen D Cancer; 1993 Jul; 72(1):244-8. PubMed ID: 8389666 [TBL] [Abstract][Full Text] [Related]
20. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. Wynick D; Bloom SR J Clin Endocrinol Metab; 1991 Jul; 73(1):1-3. PubMed ID: 1646213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]